Sub License Agreement With Mll Munchner Leukamielabor was Cardiff Oncology’s largest revenue line in fiscal 2014, bringing in $81.00K of $278.00K (29%).
| Type of Arrangement and Non-arrangement Transactions | FY 2012 | FY 2014 |
|---|---|---|
| Sub License Agreement With Ipsogen Sas | $180.00K | $60.00K |
| Sub License Agreement With Mll Munchner Leukamielabor | $71.00K | $81.00K |
| Sub License Agreement With Genoptix Inc | $100.00K | $30.00K |
| Sub License Agreement With Asuragen Inc | $50.00K | $50.00K |
| Sub License Agreement With Lab Corp | — | $28.00K |
| Sub License Agreement With In Vivo Scribe Technologies Inc | $27.00K | — |
| Sub License Agreement With Quest Diagnostics | $20.00K | $26.00K |
| Sub License Agreement With Fairview Health Services | $2.00K | $2.00K |
| Sub License Agreement With Duke University & Duke University Health Systems | — | $1.00K |
| Total | $450.00K | $278.00K |
Cardiff Oncology brought in $278.00K from its eight revenue lines in fiscal 2014, the year ended December 31, 2014. Cardiff Oncology regrouped these revenue lines after fiscal 2012, so the total does not compare directly with that year's $450.00K. Sub License Agreement With Mll Munchner Leukamielabor was the largest at $81.00K (29.1%), ahead of Sub License Agreement With Ipsogen Sas at $60.00K (21.6%) and Sub License Agreement With Asuragen Inc at $50.00K (18.0%). The other five revenue lines brought in $87.00K combined.
Compared with fiscal 2012, the previous year with figures, Sub License Agreement With Quest Diagnostics grew fastest, up 30.0% to $26.00K, while Sub License Agreement With Genoptix Inc fell the most, down 70.0% to $30.00K.
Cardiff Oncology began breaking out Sub License Agreement With Lab Corp in fiscal 2014 and Sub License Agreement With Duke University & Duke University Health Systems in fiscal 2014. Cardiff Oncology stopped reporting Sub License Agreement With In Vivo Scribe Technologies Inc as a separate revenue line after fiscal 2012, when it brought in $27.00K.
Cardiff Oncology (CRDF) reports its revenue by type of arrangement and non-arrangement transactions. In fiscal 2014, Sub License Agreement With Mll Munchner Leukamielabor was its largest revenue line, bringing in $81.00K (29.1% of the total), followed by Sub License Agreement With Ipsogen Sas at $60.00K (21.6%).
Sub License Agreement With Mll Munchner Leukamielabor was Cardiff Oncology's largest revenue line in fiscal 2014, bringing in $81.00K, or 29.1% of the $278.00K total across its eight revenue lines.
Every figure comes from Cardiff Oncology's annual financial filings, as reported. Each line keeps the name Cardiff Oncology gives it, and years follow its fiscal calendar.
Cardiff Oncology's revenue by type of arrangement and non-arrangement transactions goes back to fiscal 2012, with figures through fiscal 2014. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.